[A15-51] Belatacept - Addendum to Commission A15-25
Last updated 07.01.2016
Project no.: A15-51
Commission: Commission awarded on 24.11.2015 by the Federal Joint Committee (G-BA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.